检索问题
SIBO 是什么？
SIBO（小肠细菌过度生长）并不是一种被某种神秘细菌感染的疾病，而是一场发生在人体肠道内的“生态灾难”——原本应该生活在“下游”大肠里的细菌，错误地搬家到了“上游”的小肠，并在那里大量繁殖，导致人体无法正常吸收营养，反而产生大量气体和毒素。
简单来说，SIBO 就是细菌出现在了错误的地方。这是一种会导致腹胀、腹痛、腹泻或营养不良的消化系统疾病 。
为了让你彻底明白这究竟是怎么回事，我们把复杂的医学知识拆解开来，用最通俗的语言来讲讲 SIBO 的前因后果。
一、 核心概念：肠道里的“违章建筑”
要理解 SIBO，你首先得想象一下我们的消化系统像是一条长长的“食品加工流水线”。
- 小肠（The Small Intestine）： 这是流水线的核心“吸收车间”。在这里，食物被分解，营养被吸收进入血液。为了保证高效吸收，这里通常是非常干净的，细菌数量相对较少 。
- 大肠（The Large Intestine/Colon）： 这是流水线的末端“废物处理与发酵车间”。这里住着数以万亿计的细菌（菌群），它们负责处理剩下的食物残渣，将其发酵。
发生了什么问题？ 在 SIBO 患者体内，大肠里的那些细菌“逆流而上”，或者小肠里原本稀少的细菌开始疯狂繁殖。小肠这个“吸收车间”被细菌占领了，变成了像大肠一样的“发酵车间” 。
后果是什么？ 当你吃下食物（尤其是淀粉、糖类）时，这些占据小肠的细菌会抢在你之前把食物吃掉。细菌吃完后会“打嗝”和“放屁”，产生大量的气体（氢气、甲烷等）。因为小肠空间狭窄，这些气体无处可去，就会把你的小肠像气球一样吹起来，导致剧烈的腹胀和疼痛 。
二、 身体怎么了？（症状与感受）
如果你有 SIBO，你的身体通常会发出非常嘈杂的抗议信号。最典型的表现就是肚子里的“气体工厂”失控了。
- 极度腹胀与胀气（Bloating & Gas）： 这是最常见的症状。你可能会觉得自己像吞了一个篮球，尤其是在吃完饭后。研究显示，治疗 SIBO 后，这种气体水平会显著下降 。
- 腹痛与腹部不适： 肠道被气体撑开，会引起痉挛和疼痛 。
- 腹泻或便秘：
- 如果细菌主要产生氢气，通常会引起腹泻（跑厕所很频繁）。
- 如果微生物主要产生甲烷（严格来说这叫“产甲烷菌过度生长”，IMO），通常会导致顽固的便秘 。
- 营养不良与体重变化： 因为细菌抢走了你的营养，你可能会发现自己虽然吃得不少，但还是缺铁、缺维生素B12，甚至莫名其妙地消瘦；或者因为代谢紊乱而体重增加 。
- 脑雾与疲劳： 肠道不仅是消化器官，还影响大脑。细菌产生的毒素进入血液，会让你觉得头脑昏沉、反应迟钝，甚至引发像酒渣鼻（面部潮红）这样的皮肤问题 。
三、 为什么会得 SIBO？（原因揭秘）
正常人的小肠有几道“防线”来阻止细菌过度生长，比如胃酸能杀菌，肠道蠕动能把细菌扫走。SIBO 的发生，通常是因为这些防线崩溃了：
-
“清洁工”罢工了（肠道蠕动减慢）： 我们的肠道有一套自动清洁机制，叫“移行运动复合波”（Migrating Motor Complex）。它像扫把一样，在两顿饭之间把残留的食物和细菌扫进大肠。如果这个机制失灵（比如因为糖尿病、帕金森病或仅仅是年龄增长），食物残渣就会堆积在小肠里，成为细菌的温床 。这就像家里的垃圾没人倒，自然会招来苍蝇。
-
“门卫”睡着了（胃酸减少）： 胃酸是第一道杀菌防线。长期服用质子泵抑制剂（PPIs，一种常见的胃药） 会抑制胃酸分泌，导致细菌更容易活着进入小肠。研究明确指出，PPI 治疗是 SIBO 的显著风险因素 。
-
饮食习惯不好： 现代的西方饮食（高糖、低纤维）对肠道非常不友好。过多的糖分是细菌的最爱，而缺乏纤维会让肠道蠕动变慢 。
-
结构问题或手术： 如果做过胃旁路手术、切除过部分肠道，或者有小肠憩室（肠壁上的小口袋），都可能改变肠道结构，让细菌更容易积聚 。
四、 怎么知道自己有没有 SIBO？（诊断方法）
医生通常不会直接切开肚子去数细菌，而是用更聪明的方法：
-
呼气测试（Breath Testing）： 这是目前临床上最常用的方法，无创且便宜。
- 原理： 人体自身细胞是不产生氢气或甲烷的。你喝下一杯糖水（葡萄糖或乳果糖），如果你的小肠里有太多细菌，它们会迅速发酵这些糖，产生氢气或甲烷。这些气体会进入血液，最后通过呼吸排出来。
- 过程： 医生让你对着仪器吹气，检测气体浓度。如果短时间内气体飙升，就说明你是 SIBO 阳性 。
-
小肠液抽吸培养（Small Bowel Aspirate）： 这被认为是“金标准”，但因为要把管子插进小肠吸取液体来培养细菌，过程比较痛苦且昂贵，所以不如呼气测试普及 。
五、 怎么把“不速之客”请出去？（治疗方案）
SIBO 的治疗就像治理杂草丛生的花园，需要多管齐下：除草（杀菌）、施肥（修复环境）和甚至重新种植（调节菌群）。
1. 抗生素治疗（化学除草）
这是传统的一线治疗。医生常用一种特殊的抗生素叫做利福昔明（Rifaximin）。
- 为什么用它？ 这种抗生素很特别，它几乎不被身体吸收，只在肠道里起作用，像是定点清除肠道细菌的“狙击手”，副作用相对较小 。
- 效果： 研究显示，它能有效改善大约 33% 到 92% 患者的症状，并且能清除高达 84% 患者体内的细菌过度生长 。
2. 草本植物疗法（天然除草）
对于担心抗生素副作用的人来说，这是一个令人振奋的消息。科学研究表明，某些天然草本植物的抗菌效果不输给抗生素。
- 证据： 一项临床研究对比了草本疗法（如牛至油、小檗碱/黄连素等复方制剂）和抗生素利福昔明。结果发现，草本疗法的治愈率（46%）甚至略高于抗生素组（34%），而且副作用一样很低 。
- 小檗碱（Berberine）： 这是一种从植物中提取的成分，正在被广泛研究用于治疗 SIBO，因为它能调节肠道菌群并减少炎症 。
3. 饮食调整（断绝粮草）
想饿死细菌，就要切断它们的食物来源。
- 低 FODMAP 饮食： 这是一种限制“可发酵碳水化合物”的饮食法。简单说，就是少吃那些容易产气的洋葱、大蒜、某些豆类和小麦制品。虽然这主要用于缓解症状，不能单靠它根治 SIBO，但能让你舒服很多 。
- 元素饮食（Elemental Diet）： 这是一种极端的流食疗法，食物已经被分解成最基础的氨基酸和单糖，在细菌吃到之前就被小肠完全吸收了。这能有效“饿死”细菌，但口感较差，很难坚持 。
4. 益生菌（Probiotics）：是敌是友？
关于是否在 SIBO 期间吃益生菌，目前争议很大。
- 有些研究认为益生菌能帮助赶走坏细菌，甚至不仅能减少气体，还能提高临床治愈率 。
- 但也有专家担心，在小肠本来就细菌过多的情况下再“加菌”，无异于火上浇油。因此，使用益生菌需要非常谨慎，最好在医生指导下进行 。
六、 总结与建议
SIBO 是小肠里的细菌过剩，它会让你的肚子变成充气球，影响营养吸收。
- 不要忽视： 它是真实存在的生理问题，不是你心理作用。
- 可以治疗： 无论是吃抗生素（如利福昔明）还是天然草本（如小檗碱、牛至油），都有很高的治愈希望。
- 生活方式是关键： 治好 SIBO 只是第一步，要防止复发，你需要关注肠道蠕动（比如两餐之间留出足够时间让“清洁波”工作），少吃精制糖，多吃健康的纤维，保护好你的消化道“流水线” 。
References
1Do Herbal Supplements and Probiotics Complement Antibiotics and Diet in the Management of SIBO? A Randomized Clinical Trial.PubMed
Lucia Redondo-Cuevas, Lucia Belloch, Vanesa Martín-Carbonell, et al.
Nutrients. 2024 Apr 7;16(7):1083. doi: 10.3390/nu16071083.
Small intestinal bacterial overgrowth (SIBO) arises from dysbiosis in the small intestine, manifesting with abdominal symptoms. This study aims to assess the efficacy of combined antibiotic therapy, herbal supplements, probiotics, and dietary modifications in SIBO management. A total of 179 SIBO-diagnosed patients underwent clinical evaluation and breath testing. Patients were categorized into hydrogen (H-SIBO) and methane (CH-SIBO) groups. The control group received standard antibiotic therapy and a low-FODMAP diet, while the intervention group received additional herbal antibiotics, probiotics, and prebiotics. After treatment, both groups exhibited reduced gas levels, particularly in CH-SIBO. Clinical remission rates were higher in the intervention group, especially in CH-SIBO cases. Logistic regression analysis showed gas concentrations at diagnosis as significant predictors of treatment success. In conclusion, adjunctive herbal supplements and probiotics did not significantly impact gas levels, but showed potential for clinical improvement, especially in CH-SIBO.
2Small intestinal bacterial overgrowth: current update.PubMed
Hammad Zafar, Brenda Jimenez, Alison Schneider
Curr Opin Gastroenterol. 2023 Nov 1;39(6):522-528. doi: 10.1097/MOG.0000000000000971. Epub 2023 Sep 18.
PURPOSE OF REVIEW: This article aims to provide an up-to-date review of small intestinal bacterial overgrowth (SIBO), including etiology and risk factors, clinical manifestations, diagnostic evaluation for suspected SIBO, and therapeutic options. RECENT FINDINGS: Recent advances in breath testing, capsule and urine-based testing have opened new avenues and improved diagnostic yield of SIBO. Nonantibiotic-based treatment strategies have shown promising results in initial trials. SUMMARY: Small intestinal bacterial overgrowth (SIBO) is a condition defined by the excess bacteria or changes in bacterial composition of the small intestine. These are associated with various gastrointestinal (GI) symptoms such as bloating, abdominal distension, diarrhea, nutrient deficiencies, and even frank weight loss. Small bowel jejunal aspirate of >10 5 CFU/ml has traditionally been considered the gold standard for diagnosis. Glucose and lactulose breath testing have become more common in clinical practice as they are noninvasive, easily accessible, and have lower cost. Treatment focuses on the eradication of excess bacteria in the small bowel and is traditionally done with the use of oral antibiotics. Other emerging therapies may include probiotics, diet manipulation, and prokinetic agents.
3The importance of food quality, gut motility, and microbiome in SIBO development and treatment.PubMed
Eliza Knez, Kornelia Kadac-Czapska, Małgorzata Grembecka
Nutrition. 2024 Aug;124:112464. doi: 10.1016/j.nut.2024.112464. Epub 2024 Apr 5.
The prevalence of small intestinal bacterial overgrowth (SIBO) is rising worldwide, particularly in nations with high rates of urbanization. Irritable bowel syndrome, inflammatory bowel illnesses, and nonspecific dysmotility are strongly linked to SIBO. Moreover, repeated antibiotic therapy promotes microorganisms' overgrowth through the development of antibiotic resistance. The primary cause of excessive fermentation in the small intestine is a malfunctioning gastrointestinal motor complex, which results in the gut's longer retention of food residues. There are anatomical and physiological factors affecting the functioning of the myoelectric motor complex. Except for them, diet conditions the activity of gastrointestinal transit. Indisputably, the Western type of nutrition is unfavorable. Some food components have greater importance in the functioning of the gastrointestinal motor complex than others. Tryptophan, an essential amino acid and precursor of the serotonin hormone, accelerates intestinal transit, and gastric emptying, similarly to fiber and polyphenols. Additionally, the effect of food on the microbiome is important, and diet should prevent bacterial overgrowth and exhibit antimicrobial effects against pathogens. Therefore, knowledge about proper nutrition is essential to prevent the development and recurrence of SIBO. Since the scientific world was unsure whether there was a long-term or potential solution for SIBO until quite recently, research on a number of the topics included in the article should be performed. The article aimed to summarize current knowledge about proper nutrition after SIBO eradication and the prevention of recurrent bacterial overgrowth. Moreover, a connection was found between diet, gut dysmotility, and SIBO.
4Small Intestinal Bacterial Overgrowth: Clinical Features and Therapeutic Management.PubMed
Satish S C Rao, Jigar Bhagatwala
Clin Transl Gastroenterol. 2019 Oct;10(10):e00078. doi: 10.14309/ctg.0000000000000078.
Small intestinal bacterial overgrowth (SIBO) is a common, yet underrecognized, problem. Its prevalence is unknown because SIBO requires diagnostic testing. Although abdominal bloating, gas, distension, and diarrhea are common symptoms, they do not predict positive diagnosis. Predisposing factors include proton-pump inhibitors, opioids, gastric bypass, colectomy, and dysmotility. Small bowel aspirate/culture with growth of 10-10 cfu/mL is generally accepted as the "best diagnostic method," but it is invasive. Glucose or lactulose breath testing is noninvasive but an indirect method that requires further standardization and validation for SIBO. Treatment, usually with antibiotics, aims to provide symptom relief through eradication of bacteria in the small intestine. Limited numbers of controlled studies have shown systemic antibiotics (norfloxacin and metronidazole) to be efficacious. However, 15 studies have shown rifaximin, a nonsystemic antibiotic, to be effective against SIBO and well tolerated. Through improved awareness and scientific rigor, the SIBO landscape is poised for transformation.
5[Small intestinal bacterial overgrowth (SIBO) - Therapy, nutrition, microbiome].PubMed
Gernot Sellge, Johann Ockenga
Dtsch Med Wochenschr. 2024 Sep;149(18):1071-1079. doi: 10.1055/a-2205-5794. Epub 2024 Aug 29.
SIBO (small intestinal bacterial overgrowth) is defined by bacterial overgrowth or colonization of the small intestine in combination with gastrointestinal symptoms such as bloating, nausea, pain, diarrhoea, malabsorption and food intolerance. SIBO can be caused by various mechanisms such as reduced intestinal motility, altered gastrointestinal anatomy, reduced gastric acid or pancreatic enzyme production, altered bile acid metabolism, or immune defects. Accordingly, SIBO often develops secondary to different underlying diseases.Diet has a fundamental influence on the composition of the intestinal microbiome and is therefore also a potential pathomechanism in SIBO. Furthermore, food intolerances are common in SIBO patients. However, both aspects have so far been insufficiently investigated. Nevertheless, elemental diets, carbohydrate-reduced diets, as well as pre- and probiotics are potential therapy options.This article provides a summary of current knowledge on the pathophysiology, diagnosis and treatment of SIBO, with particular emphasis on the role of nutrition and the microbiome.
6Identification of SIBO Subtypes along with Nutritional Status and Diet as Key Elements of SIBO Therapy.PubMed
Justyna Paulina Wielgosz-Grochowska, Nicole Domanski, Małgorzata Ewa Drywień
Int J Mol Sci. 2024 Jul 4;25(13):7341. doi: 10.3390/ijms25137341.
Small intestinal bacterial overgrowth (SIBO) is a pathology of the small intestine and may predispose individuals to various nutritional deficiencies. Little is known about whether specific subtypes of SIBO, such as the hydrogen-dominant (H+), methane-dominant (M+), or hydrogen/methane-dominant (H+/M+), impact nutritional status and dietary intake in SIBO patients. The aim of this study was to investigate possible correlations between biochemical parameters, dietary nutrient intake, and distinct SIBO subtypes. This observational study included 67 patients who were newly diagnosed with SIBO. Biochemical parameters and diet were studied utilizing laboratory tests and food records, respectively. The H+/M+ group was associated with low serum vitamin D ( < 0.001), low serum ferritin ( = 0.001) and low fiber intake ( = 0.001). The M+ group was correlated with high serum folic acid ( = 0.002) and low intakes of fiber ( = 0.001) and lactose ( = 0.002). The H+ group was associated with low lactose intake ( = 0.027). These results suggest that the subtype of SIBO may have varying effects on dietary intake, leading to a range of biochemical deficiencies. Conversely, specific dietary patterns may predispose one to the development of a SIBO subtype. The assessment of nutritional status and diet, along with the diagnosis of SIBO subtypes, are believed to be key components of SIBO therapy.
7Efficacy of an Irritable Bowel Syndrome Diet in the Treatment of Small Intestinal Bacterial Overgrowth: A Narrative Review.PubMed
Justyna Paulina Wielgosz-Grochowska, Nicole Domanski, Małgorzata Ewa Drywień
Nutrients. 2022 Aug 17;14(16):3382. doi: 10.3390/nu14163382.
Small intestinal bacterial overgrowth (SIBO) is highly prevalent in irritable bowel syndrome (IBS). The eradication of bacterial overgrowth with antibiotics is the first-line treatment. However, focusing only on the antimicrobial effects without taking care to improve lifestyle factors, especially dietary patterns, may predispose patients to intestinal microbiota dysfunction. The objective of this study is to determine whether the current recommendations regarding nutrition in IBS are suitable for patients with SIBO. A narrative literature review was carried out using databases, including PubMed, ScienceDirect and Google Scholar. Recent studies indicate that dietary manipulation may have a role in alleviating SIBO gastrointestinal symptoms. A low FODMAP diet proposed for IBS may promote a negative shift in the gut microbiota and deepen the existing state of dysbiosis in SIBO patients. Supplementation with soluble fiber can lessen the symptoms in IBS and SIBO. Targeted probiotic therapy may also increase the effectiveness of antibiotic treatment and regulate bowel movements. Therefore, optimal dietary patterns play a key role in the treatment of SIBO. Based on currently available literature, the potential efficacy of the IBS diet in SIBO is largely hypothetical. Future research is needed to characterize a specific diet for the treatment of SIBO.
8Small Intestinal Bacterial Overgrowth-Pathophysiology and Its Implications for Definition and Management.PubMed
Daniel Bushyhead, Eamonn M M Quigley
Gastroenterology. 2022 Sep;163(3):593-607. doi: 10.1053/j.gastro.2022.04.002. Epub 2022 Apr 7.
The concept of small intestinal bacterial overgrowth (SIBO) arose in the context of maldigestion and malabsorption among patients with obvious risk factors that permitted the small bowel to be colonized by potentially injurious colonic microbiota. Such colonization resulted in clinical signs, symptoms, and laboratory abnormalities that were explicable within a coherent pathophysiological framework. Coincident with advances in medical science, diagnostic testing evolved from small bowel culture to breath tests and on to next-generation, culture-independent microbial analytics. The advent and ready availability of breath tests generated a dramatic expansion in both the rate of diagnosis of SIBO and the range of associated gastrointestinal and nongastrointestinal clinical scenarios. However, issues with the specificity of these same breath tests have clouded their interpretation and aroused some skepticism regarding the role of SIBO in this expanded clinical repertoire. Furthermore, the pathophysiological plausibility that underpins SIBO as a cause of maldigestion/malabsorption is lacking in regard to its purported role in irritable bowel syndrome, for example. One hopes that the application of an ever-expanding armamentarium of modern molecular microbiology to the human small intestinal microbiome in both health and disease will ultimately resolve this impasse and provide an objective basis for the diagnosis of SIBO.
9Epidemiology of small intestinal bacterial overgrowth.PubMed
Irina Efremova, Roman Maslennikov, Elena Poluektova, et al.
World J Gastroenterol. 2023 Jun 14;29(22):3400-3421. doi: 10.3748/wjg.v29.i22.3400.
Small intestinal bacterial overgrowth (SIBO) is defined as an increase in the bacterial content of the small intestine above normal values. The presence of SIBO is detected in 33.8% of patients with gastroenterological complaints who underwent a breath test, and is significantly associated with smoking, bloating, abdominal pain, and anemia. Proton pump inhibitor therapy is a significant risk factor for SIBO. The risk of SIBO increases with age and does not depend on gender or race. SIBO complicates the course of a number of diseases and may be of pathogenetic significance in the development of their symptoms. SIBO is significantly associated with functional dyspepsia, irritable bowel syndrome, functional abdominal bloating, functional constipation, functional diarrhea, short bowel syndrome, chronic intestinal pseudo-obstruction, lactase deficiency, diverticular and celiac diseases, ulcerative colitis, Crohn's disease, cirrhosis, metabolic-associated fatty liver disease (MAFLD), primary biliary cholangitis, gastroparesis, pancreatitis, cystic fibrosis, gallstone disease, diabetes, hypothyroidism, hyperlipidemia, acromegaly, multiple sclerosis, autism, Parkinson's disease, systemic sclerosis, spondylarthropathy, fibromyalgia, asthma, heart failure, and other diseases. The development of SIBO is often associated with a slowdown in orocecal transit time that decreases the normal clearance of bacteria from the small intestine. The slowdown of this transit may be due to motor dysfunction of the intestine in diseases of the gut, autonomic diabetic polyneuropathy, and portal hypertension, or a decrease in the motor-stimulating influence of thyroid hormones. In a number of diseases, including cirrhosis, MAFLD, diabetes, and pancreatitis, an association was found between disease severity and the presence of SIBO. Further work on the effect of SIBO eradication on the condition and prognosis of patients with various diseases is required.
10AGA Clinical Practice Update on Small Intestinal Bacterial Overgrowth: Expert Review.PubMed
Eamonn M M Quigley, Joseph A Murray, Mark Pimentel
Gastroenterology. 2020 Oct;159(4):1526-1532. doi: 10.1053/j.gastro.2020.06.090. Epub 2020 Jul 15.
DESCRIPTION: Thanks to ready access to hydrogen breath testing, small intestinal bacterial overgrowth (SIBO) is now commonly diagnosed among individuals presenting with a variety of gastrointestinal and even nongastrointestinal symptoms and is increasingly implicated in lay press and media in the causation of a diverse array of disorders. Its definition, however, remains controversial and true prevalence, accordingly, undefined. The purpose of this review, therefore, was to provide a historical background to the concept of SIBO, critically review current concepts of SIBO (including symptomatology, pathophysiology, clinical consequences, diagnosis and treatment), define unanswered questions and provide a road map toward their resolution. METHODS: Best Practice Advice statements were developed following discussion by the 3 authors. Two authors each developed text around certain Best Practice Advice based on a review of available literature. All 3 authors reviewed the complete draft and after discussion, redrafting, and further review and revision, all of the authors agreed on a final draft. BEST PRACTICE ADVICE 1: The definition of SIBO as a clinical entity lacks precision and consistency; it is a term generally applied to a clinical disorder where symptoms, clinical signs, and/or laboratory abnormalities are attributed to changes in the numbers of bacteria or in the composition of the bacterial population in the small intestine. BEST PRACTICE ADVICE 2: Symptoms traditionally linked to SIBO include bloating, diarrhea, and abdominal pain/discomfort. Steatorrhea may be seen in more severe cases. BEST PRACTICE ADVICE 3: There is insufficient evidence to support the use of inflammatory markers, such as fecal calprotectin to detect SIBO. BEST PRACTICE ADVICE 4: Laboratory findings can include elevated folate and, less commonly, vitamin B-12 deficiency, or other nutritional deficiencies. BEST PRACTICE ADVICE 5: A major impediment to our ability to accurately define SIBO is our limited understanding of normal small intestinal microbial populations-progress in sampling technology and techniques to enumerate bacterial populations and their metabolic products should provide much needed clarity. BEST PRACTICE ADVICE 6: Controversy remains concerning the role of SIBO in the pathogenesis of common functional symptoms, such as those regarded as components of irritable bowel syndrome. BEST PRACTICE ADVICE 7: Management should focus on the identification and correction (where possible) of underlying causes, correction of nutritional deficiencies, and the administration of antibiotics. This is especially important for patients with significant maldigestion and malabsorption. BEST PRACTICE ADVICE 8: Although irritable bowel syndrome has been shown to respond to therapy with a poorly absorbed antibiotic, the role of SIBO or its eradication in the genesis of this response warrants further confirmation in randomized controlled trials. BEST PRACTICE ADVICE 9: There is a limited database to guide the clinician in developing antibiotic strategies for SIBO, in any context. Therapy remains, for the most part, empiric but must be ever mindful of the potential risks of long-term broad-spectrum antibiotic therapy.
11Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth.PubMed
Victor Chedid, Sameer Dhalla, John O Clarke, et al.
Glob Adv Health Med. 2014 May;3(3):16-24. doi: 10.7453/gahmj.2014.019.
OBJECTIVE: Patients with small intestine bacterial overgrowth (SIBO) have chronic intestinal and extraintestinal symptomatology which adversely affects their quality of life. Present treatment of SIBO is limited to oral antibiotics with variable success. A growing number of patients are interested in using complementary and alternative therapies for their gastrointestinal health. The objective was to determine the remission rate of SIBO using either the antibiotic rifaximin or herbals in a tertiary care referral gastroenterology practice. DESIGN: One hundred and four patients who tested positive for newly diagnosed SIBO by lactulose breath testing (LBT) were offered either rifaximin 1200 mg daily vs herbal therapy for 4 weeks with repeat LBT post-treatment. RESULTS: Three hundred ninety-six patients underwent LBT for suspected SIBO, of which 251 (63.4%) were positive 165 underwent treatment and 104 had a follow-up LBT. Of the 37 patients who received herbal therapy, 17 (46%) had a negative follow-up LBT compared to 23/67 (34%) of rifaximin users (P=.24). The odds ratio of having a negative LBT after taking herbal therapy as compared to rifaximin was 1.85 (CI=0.77-4.41, P=.17) once adjusted for age, gender, SIBO risk factors and IBS status. Fourteen of the 44 (31.8%) rifaximin non-responders were offered herbal rescue therapy, with 8 of the 14 (57.1%) having a negative LBT after completing the rescue herbal therapy, while 10 non-responders were offered triple antibiotics with 6 responding (60%, P=.89). Adverse effects were reported among the rifaximin treated arm including 1 case of anaphylaxis, 2 cases of hives, 2 cases of diarrhea and 1 case of Clostridium difficile. Only one case of diarrhea was reported in the herbal therapy arm, which did not reach statistical significance (P=.22). CONCLUSION: SIBO is widely prevalent in a tertiary referral gastroenterology practice. Herbal therapies are at least as effective as rifaximin for resolution of SIBO by LBT. Herbals also appear to be as effective as triple antibiotic therapy for SIBO rescue therapy for rifaximin non-responders. Further, prospective studies are needed to validate these findings and explore additional alternative therapies in patients with refractory SIBO.
12Berberine and rifaximin effects on small intestinal bacterial overgrowth: Study protocol for an investigator-initiated, double-arm, open-label, randomized clinical trial (BRIEF-SIBO study).PubMed
Huaizhu Guo, Siqi Lu, Jindong Zhang, et al.
Front Pharmacol. 2023 Feb 15;14:1121435. doi: 10.3389/fphar.2023.1121435. eCollection 2023.
Small intestinal bacterial overgrowth (SIBO) leads to non-specific abdominal discomfort and nutrient malabsorption. Currently, rifaximin is widely applied in SIBO based on its antibacterial and non-absorbable nature. Berberine is a natural component of many popular medicine plants that ameliorates intestinal inflammation in humans through its modification of the gut microbiota. Potential effect of berberine to the gut may provide therapeutic target for SIBO. We aimed to evaluate the effect of berberine compared with rifaximin on SIBO patients. This is an investigator-initiated, single-center, open-label, double-arm randomized controlled trial, termed BRIEF-SIBO (Berberine and rifaximin effects for small intestinal bacterial overgrowth). In total, 180 patients will be recruited and allocated to an intervention group (berberine) and a control group (rifaximin). Each participant will receive one 400 mg drug twice a day (800 mg daily) for 2 weeks. The total follow-up period is 6 weeks from the start of medication. The primary outcome is a negative breath test. The secondary outcomes include abdominal symptom relief and alteration in gut microbiota. Efficacy assessment will be performed every 2 weeks, as well as safety assessment during the treatment. The primary hypothesis is that berberine is not inferior to rifaximin for SIBO. The BRIEF-SIBO study is the first clinical trial assessing the eradication effects of 2 weeks of berberine treatment in SIBO patients. The effect of berberine will be fully verified by using rifaximin as the positive control. The findings of this study may have implications for the management of SIBO, especially increasing the awareness of both physicians and patients who are suffering from long-term abdominal discomfort and avoiding excessive examination.
13Review of rifaximin as treatment for SIBO and IBS.PubMed
Mark Pimentel
Expert Opin Investig Drugs. 2009 Mar;18(3):349-58. doi: 10.1517/13543780902780175.
BACKGROUND: Rifaximin is a broad-range, gastrointestinal-specific antibiotic that demonstrates no clinically relevant bacterial resistance. Therefore, rifaximin may be useful in the treatment of gastrointestinal disorders associated with altered bacterial flora, including irritable bowel syndrome (IBS) and small intestinal bacterial overgrowth (SIBO). OBJECTIVE: To review rifaximin for treatment of IBS and SIBO. METHODS: Review of rifaximin clinical trials. RESULTS/CONCLUSION: Rifaximin improved global symptoms in 33 - 92% of patients and eradicated SIBO in up to 84% of patients with IBS, with results sustained up to 10 weeks post-treatment. Rifaximin caused a lower number of adverse events compared with metronidazole or levofloxacin and may have a more favorable adverse event profile than systemic antibiotics, without clinically relevant antibiotic resistance.
14An Oral Botanical Supplement Improves Small Intestinal Bacterial Overgrowth (SIBO) and Facial Redness: Results of an Open-Label Clinical Study.PubMed
Mildred Min, Dawnica Nadora, Mincy Chakkalakal, et al.
Nutrients. 2024 Sep 18;16(18):3149. doi: 10.3390/nu16183149.
BACKGROUND: Small intestinal bacterial overgrowth (SIBO) is a common, yet underdiagnosed, gut condition caused by gut dysbiosis. A previous study has shown the potential of herbal therapy, providing equivalent results to rifaximin. OBJECTIVES: The objective of this study was to assess how the use of an oral botanical regimen may modulate the gut microbiome, facial erythema, and intestinal permeability in those with SIBO. METHODS: This was an open-label prospective study of adults that had lactulose breath test-confirmed SIBO. Participants received a 10-week oral supplementation of a Biocidin liquid tincture and GI Detox+. If participants were found to be non-responsive to treatment after 10 weeks with a persistently positive lactulose breath test, a third oral supplement, Olivirex, was administered for an additional 4 weeks. Lactulose breath tests were administered at baseline, weeks 6, 10, and 14 to assess for SIBO status. A high-resolution photographic analysis system was utilized to analyze changes in facial erythema. Stool sample collections and venipuncture were performed to analyze the gut microbiome and intestinal permeability. RESULTS: A total of 33 subjects were screened with breath testing, and 19 subjects were found to have SIBO. Three of the subjects withdrew during the screening period prior to baseline, and sixteen subjects enrolled. Four subjects dropped out after baseline. Hydrogen-dominant SIBO was the most common subtype of SIBO, followed by methane and hydrogen sulfide. The botanical regimen was most effective for hydrogen- and hydrogen sulfide-dominant SIBO, leading to negative breath test results at week 10 in 42.8% and 66.7% of participants, respectively. Compared to baseline, supplementation with the botanical regimen led to positive shifts in short-chain fatty acid-producing bacteria such as , , , and by 31.4%, 35.4%, 24.8%, and 48.7% percent at week 10, respectively. The mean abundance of decreased by 20.2%, increased by 30%, and the F/B ratio decreased by 25.4% at week 10 compared to baseline. At week 10, there was a trending 116% increase in plasma LPS/IgG ( = 0.08). There were no significant changes in plasma zonulin, DAO, histamine, DAO/histamine, LPS/IgG, LPS/IgA, or LPS/IgM. Facial erythema was not statistically different at week 6, but at week 10, there was a 20% decrease ( = 0.001) in redness intensity. Among the patients that extended to week 14, there was no statistical change in erythema. CONCLUSIONS: Supplementation with an antimicrobial botanical supplemental regimen may have therapeutic potential in hydrogen and hydrogen-sulfide subtypes of SIBO. Furthermore, the botanical supplemental regimen may reduce facial erythema, increase SCFA-producing bacteria, decrease the F/B ratio, and modulate markers of intestinal permeability.
15Alternative Treatment Approaches to Small Intestinal Bacterial Overgrowth: A Systematic Review.PubMed
Melissa A Nickles, Aliza Hasan, Anastasia Shakhbazova, et al.
J Altern Complement Med. 2021 Feb;27(2):108-119. doi: 10.1089/acm.2020.0275. Epub 2020 Oct 19.
Broad-spectrum antibiotics are the first-line treatment for small intestinal bacterial overgrowth (SIBO). However, many antibiotics have a considerable side-effect profile and SIBO commonly reoccurs after successful eradication with antibiotics. Alternative therapies such as probiotics, therapeutic diets, and herbal medicines have been used to individualize SIBO management, particularly in recalcitrant cases. The objective of this review is to evaluate the role of alternative therapies in SIBO treatment. EMBASE, MEDLINE, and the Cochrane Central Register were systematically searched for clinical studies evaluating alternative therapies in the management of SIBO. Human studies in which an alternative intervention was used to treat SIBO were included. Alternative interventions were defined as an intervention that included a probiotic supplement, herbal preparation, or a dietary change. Randomized controlled trials (RCTs), nonrandomized clinical trials with or without a control, and crossover studies were included. The following information was extracted from the selected studies: study type, study participants, SIBO subtype, intervention, comparison, outcome measures, relevant results, relevant side effects, and Jadad score. Eight studies met inclusion criteria. The studies evaluated probiotics ( = 5), therapeutic diet ( = 1), and herbal medicines ( = 2). Among these studies, there were four RCTs, two open-label single-arm studies, one randomized, double-blind crossover study, and one two-arm open-label study with crossover. Main results are summarized. There may be studies not captured by the defined search criteria. Additionally, studies used different methodologies in both breath testing and measurement of clinical symptoms, making it difficult to draw conclusions on SIBO eradication and symptom improvement across studies. Our findings suggest preliminary evidence for a role of alternative therapies in the treatment of SIBO. However, robust clinical trials are generally lacking. Existing studies tend to be small and lack standardized formulations of treatment. Breath testing protocols and clinical symptom measurement greatly varied between studies. Large-scale, randomized, placebo-controlled trials are needed to further evaluate the best way to utilize alternative therapies in the treatment of SIBO.
16Diet and intestinal bacterial overgrowth: Is there evidence?PubMed
Claudineia Souza, Raquel Rocha, Helma Pinchemel Cotrim
World J Clin Cases. 2022 May 26;10(15):4713-4716. doi: 10.12998/wjcc.v10.i15.4713.
The intestinal microbiota and its role in health and disease processes have been the subject of several studies. It is known that changes in the intestinal microbiota occur due to several factors, such as the use of medication, age, lifestyle and diseases, which can modify intestinal homeostasis and lead to excessive growth of bacteria in the small intestine, triggering a clinical condition called small bowel bacterial overgrowth (SIBO). Individuals with SIBO may present gastrointestinal symptoms ranging from nausea, diarrhea and/or constipation, and flatulence to distension and abdominal pain, resulting from poor absorption of nutrients or changes in intestinal permeability. The gold-standard treatment is based on the use of antibiotics to eradicate bacterial overgrowth. Some studies have evaluated diets in the treatment of SIBO; however, the studies are of low methodological quality, making extrapolation of the results to clinical practice unfeasible. Thus, there is still not enough scientific evidence to support a specific type of diet for the treatment of SIBO.
17Small Intestinal Bacterial Overgrowth: Nutritional Implications, Diagnosis, and Management.PubMed
Abimbola Adike, John K DiBaise
Gastroenterol Clin North Am. 2018 Mar;47(1):193-208. doi: 10.1016/j.gtc.2017.09.008. Epub 2017 Dec 7.
Small intestinal bacterial overgrowth (SIBO), characterized by the presence of excessive bacteria in the small intestine, is typically described as a malabsorptive syndrome occurring in the context of gut stasis syndromes. SIBO is now considered to be a disorder associated with diverse clinical conditions without classic risk factors for SIBO and a cause of several nonspecific gastrointestinal and nongastrointestinal symptoms. Because there is currently no gold standard for diagnosing SIBO, its prevalence and role in the pathogenesis of other diseases remain uncertain; as does optimal treatment of patients with relapsing symptoms.
18Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome - An Update.PubMed
Will Takakura, Mark Pimentel
Front Psychiatry. 2020 Jul 10;11:664. doi: 10.3389/fpsyt.2020.00664. eCollection 2020.
Small intestinal bacterial overgrowth (SIBO) is one manifestation of gut microbiome dysbiosis and is highly prevalent in IBS (Irritable Bowel Syndrome). SIBO can be diagnosed either by a small bowel aspirate culture showing ≥10 colony-forming units (CFU) per mL of aspirate, or a positive hydrogen lactulose or glucose breath test. Numerous pathogenic organisms have been shown to be increased in subjects with SIBO and IBS, including but not limited to , and In addition, , the causal organism in a positive methane breath test, has been linked to constipation predominant irritable bowel syndrome (IBS-C). As is an archaeon and can overgrow in areas outside of the small intestine, it was recently proposed that the term intestinal methanogen overgrowth (IMO) is more appropriate for the overgrowth of these organisms. Due to gut microbiome dysbiosis, patients with IBS may have increased intestinal permeability, dysmotility, chronic inflammation, autoimmunity, decreased absorption of bile salts, and even altered enteral and central neuronal activity. As a consequence, SIBO and IBS share a myriad of symptoms including abdominal pain, distention, diarrhea, and bloating. Furthermore, gut microbiome dysbiosis may be associated with select neuropsychological symptoms, although more research is needed to confirm this connection. This review will focus on the role of the gut microbiome and SIBO in IBS, as well as novel innovations that may help better characterize intestinal overgrowth and microbial dysbiosis.
19Small Intestinal Bacterial and Fungal Overgrowth: Health Implications and Management Perspectives.PubMed
Natalie Soliman, Caroline Kruithoff, Erin Marie San Valentin, et al.
Nutrients. 2025 Apr 17;17(8):1365. doi: 10.3390/nu17081365.
BACKGROUND/OBJECTIVES: Small Intestinal Bacterial Overgrowth (SIBO) and Small Intestinal Fungal Overgrowth (SIFO) are distinct yet often overlapping conditions characterized by an abnormal increase in microbial populations within the small intestine. SIBO results from an overgrowth of colonic bacteria, while SIFO is driven by fungal overgrowth, primarily involving species. Both conditions present with nonspecific gastrointestinal (GI) symptoms such as bloating, abdominal pain, diarrhea, and malabsorption, making differentiation between SIBO and SIFO challenging. This review aims to elucidate the underlying mechanisms, risk factors, diagnostic challenges, and management strategies associated with SIBO and SIFO. METHODS: A comprehensive review of current literature was conducted, focusing on the pathophysiology, diagnostic modalities, and therapeutic approaches for SIBO and SIFO. RESULTS: SIBO is commonly associated with factors such as reduced gastric acid secretion, impaired gut motility, and structural abnormalities like bowel obstruction and diverticula. It is frequently diagnosed using jejunal aspirates (≥10 colony forming units (CFUs)/mL) or breath tests. In contrast, SIFO is linked to prolonged antibiotic use, immunosuppression, and gut microbiome dysbiosis, with diagnosis relying on fungal cultures from small intestinal aspirates due to the absence of standardized protocols. CONCLUSION: The clinical overlap and frequent misdiagnosis of SIBO and SIFO highlight the need for improved diagnostic tools and a multidisciplinary approach to management. This review emphasizes the importance of understanding the mechanisms behind SIBO and SIFO, how they relate to other health outcomes, and potential management strategies to optimize patient care and therapeutic outcomes.
20Show Me What You Have Inside-The Complex Interplay between SIBO and Multiple Medical Conditions-A Systematic Review.PubMed
Natalia Sroka, Alicja Rydzewska-Rosołowska, Katarzyna Kakareko, et al.
Nutrients. 2022 Dec 24;15(1):90. doi: 10.3390/nu15010090.
The microbiota, as a complex of microorganisms in a particular ecosystem, is part of the wider term-microbiome, which is defined as the set of all genetic content in the microbial community. Imbalanced gut microbiota has a great impact on the homeostasis of the organism. Dysbiosis, as a disturbance in bacterial balance, might trigger or exacerbate the course of different pathologies. Small intestinal bacterial overgrowth (SIBO) is a disorder characterized by differences in quantity, quality, and location of the small intestine microbiota. SIBO underlies symptoms associated with functional gastrointestinal disorders (FGD) as well as may alter the presentation of chronic diseases such as heart failure, diabetes, etc. In recent years there has been growing interest in the influence of SIBO and its impact on the whole human body as well as individual systems. Therefore, we aimed to investigate the co-existence of SIBO with different medical conditions. The PubMed database was searched up to July 2022 and we found 580 original studies; inclusion and exclusion criteria let us identify 112 eligible articles, which are quoted in this paper. The present SIBO diagnostic methods could be divided into two groups-invasive, the gold standard-small intestine aspirate culture, and non-invasive, breath tests (BT). Over the years scientists have explored SIBO and its associations with other diseases. Its role has been confirmed not only in gastroenterology but also in cardiology, endocrinology, neurology, rheumatology, and nephrology. Antibiotic therapy could reduce SIBO occurrence resulting not only in the relief of FGD symptoms but also manifestations of comorbid diseases. Although more research is needed, the link between SIBO and other diseases is an important pathway for scientists to follow.